Tranexamic Acid in Preventing Postpartum Hemorrhage in High Risk Pregnancies During Elective Cesarean Section

The Effect of Tranexamic Acid in Preventing Postpartum Hemorrhage in High Risk Pregnancies During Elective Cesarean Section, a Randomized Controlled Clinical Trial

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03351686

Enrollment

140

Registered

2017-11-24

Start date

2016-08-01

Completion date

2017-04-15

Last updated

2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage

Keywords

tranexamic acid

Brief summary

postpartum hemorrhage (PPT) represents one of the major causes of maternal mortality . Tranexamic acid is used in many studies in management of PPH in combination with ecobolics. this study aims to evaluate the possible value of the use of tranexamic acid in prevention of postpartum hemorrhage .

Interventions

DRUGTranexamic Acid

Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 42 Years

Healthy volunteers

Inclusion criteria

* Gestational age of 28 weeks or more. * Chronic Hypertension. * Preeclapmsia -Eclampsia. * Multiple pregnancy. * Uterine Liomyomas. * Polyhydraminos. * Fetal macrosomia. * Associated Thrombocytopenia * History of postpartum hemorrhage.

Exclusion criteria

* Patients with rheumatic heart disease. * Patients with history Cardiac Valve Replacement. * Current or past history of DVT. * Women on any anticoagulant therapy. * Sensitivity to tranexamic acid * Pregnancies with any abnormally implanted or located placenta.

Design outcomes

Primary

Measure	Time frame	Description
prevention of postpartum hemorrhage in high risk group	intraoperative	assessment of intraoperative blood loss

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026